TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02237183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iloprost
Description: Given via inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iloprost
Description: Given via inhalation

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given via inhalation

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given via inhalation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT00458302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darunavir (DRV, TMC114)
Description: 800 mg qd (2 x 400 mg tablet) + 2 NRTI for 144 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darunavir (DRV, TMC114)
Description: 800 mg qd (2 x 400 mg tablet) monotherapy for 144 weeks
Study: NCT04591626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dulaglutide
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine
Description: Administered SC
Study: NCT01711697

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiation therapy
Description: Undergo SBRT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiation therapy
Study: NCT01720641

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet
Description: Referral and user instructions for Peru section of www.inspot.org partner notification website

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Referral Card
Description: 5 printed referral cards with information on syphilis signs, symptoms, diagnosis, treatment, and local resources.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet and Referral Card
Description: 5 printed referral cards with information on syphilis signs, symptoms, diagnosis, treatment, and local resources; Referral and user instructions for Peru section of www.inspot.org partner notification website.
Study: NCT04362124

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: vaccine BCG
Description: Performance evaluation of a single dose of BCG vaccine in reducing the severity of SARS-COV-2 infection compared to placebo, in healthcare personnel.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single dose intradermal application of normal saline solution.
Study: NCT04132037

Intervention type: OTHER
Intervention: data record
Description: At each protocol's visit, clinical and urinary data will be recorded and the answers of the questionnaires will be also reported
Study: NCT00303030

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 1. Anal injection
Description: Submucosal injection just above the linea dentata in the anal canal of 4 x 1 ml of dextranomere.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 2. Biofeedback
Description: Training under the guidance of a physiotherapist with the help of a biofeedback device with an anal probe.
Study: NCT00193375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 50mg/m2 days 1 \& 8 each 21-day cycle 1 \& 2, 28-day cycle 3 \& 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 10mg/kg IV every 2 weeks for 10 doses starting week 16

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Study: NCT00072384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal vincristine sulfate
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cryosurgery
Description: Application of extreme cold to destroy abnormal or diseased tissue.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laser surgery
Description: Surgery using a laser (instead of a scalpel) to cut tissue

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given subcutaneously
Study: NCT03281772

Intervention type: OTHER
Intervention: Clinical Decision Software - provider portal
Description: As noted in Arms

Intervention type: OTHER
Intervention: Clinical Decision Software - patient portal
Description: As noted in Arms
Study: NCT04295577

Intervention type: OTHER
Intervention: Niraparib
Description: Niraparib - Niraparib is an oral, highly selective PARP-1 and -2 inhibitor. However, it also inhibits other members of the PARP family, including PARP 3, -4, -10, 12, -14, and -15\[13\].

Intervention type: OTHER
Intervention: Niraparib
Description: Niraparib - Niraparib is an oral, highly selective PARP-1 and -2 inhibitor. However, it also inhibits other members of the PARP family, including PARP 3, -4, -10, 12, -14, and -15\[13\].
Study: NCT01492348

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STEPS UP
Description: The STEPS UP intervention enhances RESPECT-Mil in several ways:~1. Adds care manager training in motivational enhancement, problem solving, and behavioral activation strategies to improve patient engagement.~2. Adds preference-based stepped care (i.e., order of steps determined by symptom severity, patient preference, \& primary care recommendation) to existing options of pharmacotherapy that includes web-based self-management programs; flexible, modularized telephone-delivered CBT; and individual face to face psychotherapy by specialist.~3. Adds option for centralized, telephone-based care management to improve fidelity of intervention delivery, continuity of care, and access to care during off-hours.~4. Adds a centralized care team using an electronic symptom registry to provide staffing to care managers, track patients longitudinally, develop stepped-based treatment recommendations, and monitor intervention components.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: OUC
Description: Service members randomized to Optimized Usual Care (OUC) will get usual treatment at the site. OUC is RESPECT-Mil, a voluntary, primary care-based implementation program based on the three-component model where, with the assistance and collaboration of a psychiatrist and an on-site nurse-level care manager, service members with symptoms of PTSD and depression are screened, tracked, and treated within the primary care system. Components of the RESPECT-Mil program include (1) equipping and training primary care clinics to screen each visit and use symptom severity tools for diagnosis and assessment; (2) using nurse care managers to assist patients and primary care clinicians; and (3) increasing access to a mental health specialist, often using a clinic specialist.
Study: NCT01635829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Description: Type=exact number, unit=mg, number=375, form=tablet, route=oral. Two tablets of telaprevir will be administered as per the dosing regimens for each part of both the panels.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Description: Type=exact number, unit=mg, number=375, form=tablet, route=oral. Two tablets of telaprevir will be administered as per the dosing regimens for each part of both the panels.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenytoin
Description: Type=exact number, unit=mg, number=100, form=capsule, route=oral. Two capsules of phenytoin will be administered as per the dosing regimen in Part 2 of Panel 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Description: Type=exact number, unit=mg, number=200, form=tablet, route=oral. One tablet of carbamazepine will be administered as per dosing regimen in Part 2 of Panel 2.
Study: NCT04198831

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: Patients receiving acupuncture and mild moxibustion, whom were treated 3 times per week for 12 weeks and followed up for 36 weeks. Bilateral ST37, SP6, SP4, LR3, KI3, LI4 and LI11 were selected for acupuncture and CV8, CV12 and bilateral ST36 were selected for moxibustion. Hwato acupuncture device was used to blind the subjects, and had the deqi sensation. The surface temperature of acupoints was maintained at 43℃± 1℃ for moxibustion.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture
Description: Patients receiving sham acupuncture and sham mild moxibustion, whom were treated 3 times per week for 12 weeks and followed up for 36 weeks. Bilateral ST37, SP6, SP4, LR3, KI3, LI4 and LI11 were selected for acupuncture and CV8, CV12 and bilateral ST36 were selected for moxibustion. Same Hwato acupuncture device was used to blind the subjects, but do not puncturing into the skin and do not have the deqi sensation. The surface temperature of acupoints was maintained at 37℃± 1℃ for moxibustion.
Study: NCT01368263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: goserelin acetate
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: goserelin acetate
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: goserelin acetate
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anastrozole
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anastrozole
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anastrozole
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy
Description: Standard chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy
Description: Standard chemotherapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Study: NCT01982695

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lisinopril
Study: NCT02965404

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational live attenuated varicella vaccine
Description: The investigational vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: control live attenuated varicella vaccine
Description: The control vaccine was manufactured by Shanghai Institute of Biological Products Co., Ltd. (SIBP)

Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: diluent of lyophilized vaccine
Description: The diluent of lyophilized vaccine was manufactured by Sinovac (Dalian) Vaccine Technology
Study: NCT02104024

Intervention type: OTHER
Intervention: Contrast Enhanced Ultrasound Scanning
Study: NCT03122691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cannabis
Description: Cannabis will be self-administered by study participants

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cannabis
Description: Cannabis will be self-administered by study participants

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cannabis
Description: Cannabis will be self-administered by study participants
Study: NCT03397043

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protein intake (dose)
Description: Protein intake, in the form of crystalline amino acids, will range between 0.2-3.0 g/kg/d
Study: NCT02357225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyridostigmine Bromide
Description: Pyridostigmine is an acetylcholinesterase inhibitor, which increases the amount of acetylcholine at the neuromuscular junction. It will be taken orally, either as a tablet or as a syrup.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyridostigmine Bromide
Description: Pyridostigmine is an acetylcholinesterase inhibitor, which increases the amount of acetylcholine at the neuromuscular junction. It will be taken orally, either as a tablet or as a syrup.
Study: NCT01518647

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: Acceptance and Commitment Therapy is a new third wawe cognitive therapy with the key treatment elements: acceptance, personal values and goals

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Acceptance and Commitment Therapy
Description: Acceptance and Commitment Therapy is a new third wawe cognitive therapy with the key treatment elements: acceptance, personal values and goals

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: Acceptance and Commitment Therapy is a new third wawe cognitive therapy with the key treatment elements: acceptance, personal values and goals
Study: NCT04025541

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood sampling
Description: blood sampling time : cycle 1 day 15 and cycle 2 day 15 : one sample (6ml) by time

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood sampling
Description: blood sampling time : cycle 1 day 15 and cycle 2 day 15 : one sample (6ml) by time
Study: NCT02983045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose Escalation Doublet: Combination of NKTR-214 + nivolumab
Description: NKTR 214 + nivolumab at 5 dosage levels.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose Expansion Doublet: Combination of NKTR-214 + nivolumab
Description: Select patient cohorts with select tumor types will be dosed with NKTR-214 + nivolumab at the RP2D + other anti-cancer therapies per institution standard.
Study: NCT02527824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin, Irinotecan, S-1
Description: Treatment will be delivered every 2 weeks~1. Oxaliplatin 65 mg/m2 iv on day 1~2. Irinotecan 135 mg/m2 iv on day 1~3. S-1 80 mg/m2/day on day1-7
Study: NCT03373942

Intervention type: OTHER
Intervention: Choroidal thickness measurements with SD-OCT device
Study: NCT02983045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Schedule Finding Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab
Description: 1L patients with RCC, NSCLC, UCC, and melanoma received NKTR-214 0.006 mg/kg q3w in combination with nivolumab and ipilimumab according to 3 dosing schedules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose Expansion Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab
Description: Combination of NKTR-214 + nivolumab + ipilimumab was administered at RP2D dose/schedules in select tumor types
Study: NCT03318198

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanged Attending Supervision
Description: Attendings were randomized at the start of the study to begin in the enhanced supervision arm where they attended resident work rounds. They then crossed over to the control arm where they did not attend work rounds. The outcomes were assessed between the two periods during which the attending participated in the study; attending work rounds vs. not attending work rounds.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: Attendings participated directly in new patient rounds but did not see patients previously known to the team with the residents.
Study: NCT00773357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: guanfacine
Description: 3 mg/day, with 3-week lead-in medication period. The starting dose is 0.5 mg/day for days 1-3, followed by 1.5mg/day for days 4-7, followed by 2 mg/day for days 8-12, followed by 2.5 mg/day for days 13-15, followed by 3 mg/day from day 16 to remainder of study. 5-day taper at end of study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT03373942

Intervention type: OTHER
Intervention: Choroidal thickness measurements with SD-OCT device

Intervention type: OTHER
Intervention: Choroidal thickness measurements with SD-OCT device
Study: NCT02631577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab (MPDL3280A) [TECENTRIQ]
Description: Atezolizumab will be administered at a flat dose of 840 mg on Days 1 and 15 of Cycles 2 to 6, given in 28-day cycles as induction treatment and 840 mg on Days 1 and 2 of each month, given as maintenance treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab (MPDL3280A) [TECENTRIQ]
Description: Atezolizumab will be administered at a flat dose of 840 mg on Days 1 and 15 of Cycles 2 to 6, given in 28-day cycles as induction treatment and 840 mg on Days 1 and 2 of each month, given as maintenance treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide will be administered orally once daily on Days 1 to 21 of Cycles 1 to 6 (28-day cycles) during induction treatment and on Days 1 to 21 of each month during maintenance treatment. Lenalidomide will be administered at a dose of 15 or 20 mg (dose may be de-escalated to 10 mg) during induction treatment and at 10 mg during maintenance treatment. During the expansion phase, lenalidomide will be administered at the RP2D during induction treatment and at 10 mg during maintenance treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide will be administered orally once daily on Days 1 to 21 of Cycles 1 to 6 (28-day cycles) during induction treatment and on Days 1 to 21 of each month during maintenance treatment. Lenalidomide will be administered at a dose of 15 or 20 mg (dose may be de-escalated to 10 mg) during induction treatment and at 10 mg during maintenance treatment. During the expansion phase, lenalidomide will be administered at the RP2D during induction treatment and at 10 mg during maintenance treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab will be administered by intravenous infusion at an absolute (flat) dose of 1000 mg on Days 1, 8, and 15 of the first cycle and on Day 1 of each subsequent cycle during induction treatment, and on Day 1 of every other month (i.e., every 2 months) during maintenance treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab will be administered by intravenous infusion at an absolute (flat) dose of 1000 mg on Days 1, 8, and 15 of the first cycle and on Day 1 of each subsequent cycle during induction treatment, and on Day 1 of every other month (i.e., every 2 months) during maintenance treatment.
Study: NCT01707745

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Intravitreal Bevacizumab
Study: NCT03738423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN3500
Description: Administered subcutaneous (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN3500
Description: Administered subcutaneous (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN3500
Description: Administered subcutaneous (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN3500
Description: Administered subcutaneous (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN3500-Matching Placebo
Description: Administered subcutaneous (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN3500-Matching Placebo
Description: Administered subcutaneous (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN3500-Matching Placebo
Description: Administered subcutaneous (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN3500-Matching Placebo
Description: Administered subcutaneous (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN3500-Matching Placebo
Description: Administered subcutaneous (SC)
Study: NCT02576119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-955176, Placebo (Part 1)
Description: The BMS-955176 dose in sentinel Cohort 1 will be 240 mg orally. The BMS-955176 dose in sentinel Cohort 2 will be determined based on the results of data from sentinel Cohort 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-955176, Moxifloxacin, Placebo (Part 2)
Description: Subjects will be randomized to 1 of 12 sequences. Each sequence includes combination of different regimens (combination of BMS-955176, placebo and Moxifloxacin).
Study: NCT00933790

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATT (Ethambutol, Pyrazinamide, INH, Rifampicin)
Description: Ethambutol 800 mg for daily, 1200 mg for intermittent therapy, Pyrazinamide 1500 mg for both daily and intermittent, INH 300 mg for daily and 600 mg for intermittent therapy, Rifampicin 450 mg for both daily and intermittent therapy for patients below 60 kg, 600 mg for both daily and intermittent therapy for patients 60 kg and above

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATT (Ethambutol, Pyrazinamide, INH, Rifampicin)
Description: Ethambutol 800 mg for daily, 1200 mg for intermittent therapy, Pyrazinamide 1500 mg for both daily and intermittent, INH 300 mg for daily and 600 mg for intermittent therapy, Rifampicin 450 mg for both daily and intermittent therapy for patients below 60 kg, 600 mg for both daily and intermittent therapy for patients 60 kg and above

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATT (Ethambutol, Pyrazinamide, INH, Rifampicin)
Description: Ethambutol 800 mg for daily, 1200 mg for intermittent therapy, Pyrazinamide 1500 mg for both daily and intermittent, INH 300 mg for daily and 600 mg for intermittent therapy, Rifampicin 450 mg for both daily and intermittent therapy for patients below 60 kg, 600 mg for both daily and intermittent therapy for patients 60 kg and above
Study: NCT04083820

Intervention type: DRUG
Intervention: semaglutide
Description: Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.